
GLOW Blend 70mg (50mg/10mg/10mg)
- Tissue repair and regeneration
- Collagen synthesis and skin remodelling

£7.45 per mg · 20mg total
Choose your pack
Certificate of analysis
Independent test results for this batch, tested by Janoshik Analytical.
Batch MRL-26Q3-A05
MS
Mass-spec confirmed identity
LAL
Endotoxin tested to established limits
UK
Synthesised and tested in Britain
Supplied as a liquid peptide solution in a 3ml research cartridge. Contains Tesamorelin (20mg). A GHRH(1-44) analogue with an N-terminal hexenoyl modification conferring resistance to DPP-IV cleavage, studied in visceral-adiposity and IGF-1 axis models.
Format
Liquid peptide solution, 20mg
Molecular formula
C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight
5135.9 g/mol
Abbreviation
TESA
A vial arrives as powder that must be prepared, measured and transferred by hand. The Mercia Pen arrives pre-filled.
Store
Store immediately at 2–8°C upon delivery. Do not freeze.
Shipping
Shipped in validated temperature-controlled packaging to maintain product stability during transit.
Avoid Freezing
Do not freeze, as freezing may compromise product quality.
Temperature Tolerance
Stabilised below 25°C for delivery. Should not be exposed to higher temperatures.
3rd Party Tested
Independently tested for heavy metals, residual solvents and endotoxins to established limits.
Full Traceability
Batch-level traceability from production to delivery.
Certificate of Analysis
Lot-matched 3rd party CoA with every batch. Available on our website.
Shelf Life
12 months from manufacture when stored at 2–8°C.
Tesamorelin is a synthetic analogue of human growth-hormone-releasing hormone (GHRH), sometimes written Tesamorelin peptide, consisting of the full 44-amino-acid sequence with a trans-3-hexenoic acid group attached to the N-terminus. Supplied here as a UK-manufactured liquid peptide solution for researchers looking to buy Tesamorelin in the UK, this modification confers resistance to DPP-IV enzymatic cleavage, extending its biological activity compared to native GHRH.
The defining characteristic of Tesamorelin in research contexts is its enhanced stability. Studies have examined how the N-terminal hexenoyl modification protects against DPP-IV cleavage, the resulting extended half-life compared to unmodified GHRH analogues, and the implications for sustained GHRH receptor engagement in preclinical models.
Tesamorelin has been studied in the context of visceral adiposity, particularly in relation to GH-mediated lipolysis in visceral adipose depots, IGF-1 axis stimulation and downstream metabolic effects, and lipodystrophy models where GH axis dysregulation affects fat distribution.
As a GHRH analogue, Tesamorelin stimulates endogenous GH secretion with downstream effects on IGF-1 production. Research has focused on hepatic IGF-1 synthesis in response to pulsatile GH stimulation, the IGF-1 binding protein profile under Tesamorelin-mediated GH pulses, and long-term axis dynamics in preclinical models.
For laboratory research use only. Not intended for human or animal consumption.
Yes. Every order ships with a third-party CoA matched to the lot number printed on your cartridge. A sample CoA is available on the site.
Each batch is HPLC-tested for purity and mass-spec confirmed for identity, then tested for heavy metals, residual solvents and endotoxins.
No. The cartridge is supplied as a ready-to-use liquid solution in 3ml bacteriostatic water.
Validated temperature-controlled packaging, UK next-day dispatch. Store at 2–8°C on arrival, do not freeze, 12-month shelf life.
Qualified personnel for in vitro laboratory research and analytical work only. Not for human or animal consumption.




